Alterity Therapeutics Limited logo
Alterity Therapeutics Limited ATHE
$ 3.56 -2.22%

Annual report 2022
added 08-31-2022

report update icon

Alterity Therapeutics Limited EPS Ratio 2011-2026 | ATHE

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Alterity Therapeutics Limited

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-0.53 -0.9 -1.5 - - - - - - - - -

All numbers in AUD currency

Indicator range from annual reports

Maximum Minimum Average
-0.53 -1.5 -0.977

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-15.4 - 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
-204 - -24.86 % $ 820 K usaUSA
AbbVie AbbVie
ABBV
1.02 $ 208.84 -2.86 % $ 369 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
-0.49 $ 3.52 0.28 % $ 1.05 B canadaCanada
Grifols, S.A. Grifols, S.A.
GRFS
0.28 $ 8.24 -0.12 % $ 6.83 B spainSpain
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-8.28 $ 229.25 0.44 % $ 5 B danmarkDanmark
I-Mab I-Mab
IMAB
-7.66 - - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
1.51 - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-0.26 - -13.47 % $ 169 M franceFrance
Aeterna Zentaris Aeterna Zentaris
AEZS
-0.07 - 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-24.9 - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-0.36 - - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-3.75 - - $ 3.67 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-31 - -18.52 % $ 27.3 M britainBritain
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
-1.04 $ 74.21 -2.3 % $ 1.43 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-6.62 - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
-7.99 - -9.65 % $ 45.9 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-1.08 $ 1.41 2.17 % $ 375 M britainBritain
AgeX Therapeutics AgeX Therapeutics
AGE
-1.91 - -10.17 % $ 12.2 K usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
-0.78 $ 1.51 48.04 % $ 17 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-3.25 - - $ 10.1 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.57 - 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
-2.52 - 0.23 % $ 488 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-0.72 - 3.16 % $ 1.9 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
1.82 $ 55.5 -3.04 % $ 10.6 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-1.73 - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-1.96 - 10.36 % $ 9.8 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-2.4 $ 8.03 2.29 % $ 220 M israelIsrael
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
-0.39 $ 14.81 2.63 % $ 2.25 B usaUSA
Altimmune Altimmune
ALT
-1 $ 3.34 7.05 % $ 294 M usaUSA
BioNTech SE BioNTech SE
BNTX
42.2 $ 91.18 1.97 % $ 27.2 B germanyGermany
Amgen Amgen
AMGN
14.3 $ 347.94 -1.51 % $ 187 B usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
1.6 $ 15.61 0.9 % $ 2.1 B canadaCanada
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
3.47 $ 59.6 -2.45 % $ 121 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-10.4 - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
-0.96 - -39.0 % $ 4.57 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-2.21 - - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
75.3 $ 4.14 -2.59 % $ 683 M britainBritain
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
-0.43 $ 9.02 -3.84 % $ 1.86 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-0.93 - -52.27 % $ 4.45 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
-1.94 $ 5.76 1.95 % $ 469 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
0.2 - 0.49 % $ 251 B cayman-islandsCayman-islands
AVROBIO AVROBIO
AVRO
0.27 - 1083.1 % $ 745 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
-2.55 $ 3.41 1.19 % $ 116 M franceFrance
Biogen Biogen
BIIB
8.83 $ 177.34 -3.5 % $ 26 B usaUSA
Axcella Health Axcella Health
AXLA
-1.49 - -16.42 % $ 249 M usaUSA
Axon Enterprise Axon Enterprise
AXON
4.98 $ 412.81 -2.54 % $ 31.3 B usaUSA